Allen Mooney & Barnes Investment Advisors LLC Has $20.63 Million Stake in AbbVie Inc. $ABBV

Key Points

• Allen Mooney & Barnes Investment Advisors reduced its AbbVie stake by 6.9% in the second quarter, selling 6,063 shares. It still held 81,986 shares valued at approximately $20.63 million, making AbbVie the firm’s third-largest holding.
• AbbVie exceeded quarterly earnings and revenue expectations, reporting $3.65 in EPS and $16.99 billion in revenue, with revenue up 10.2% year over year. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• Analysts maintain a broadly positive view, with a consensus “Moderate Buy” rating and average price target of $275.95 versus the reported share price of $251.04. AbbVie also pays a $1.73 quarterly dividend, equivalent to a 2.8% annual yield.

Allen Mooney & Barnes Investment Advisors LLC trimmed its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 6.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,986 shares of the company's stock after selling 6,063 shares during the period. AbbVie accounts for about 3.1% of Allen Mooney & Barnes Investment Advisors LLC's investment portfolio, making the stock its 3rd biggest holding. Allen Mooney & Barnes Investment Advisors LLC's holdings in AbbVie were worth $20,631,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of the stock. Norges Bank purchased a new stake in AbbVie in the fourth quarter worth about $5,865,055,000. Corient Private Wealth LP purchased a new position in shares of AbbVie during the 2nd quarter worth approximately $559,736,000. Legal & General Group Plc bought a new position in shares of AbbVie in the 2nd quarter worth approximately $2,905,952,000. Wellington Management Group LLP raised its position in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Finally, Capital World Investors lifted its stake in shares of AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company's stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares during the period. Institutional investors own 70.23% of the company's stock.

AbbVie Stock Performance

NYSE:ABBV opened at $251.04 on Thursday. The firm has a market cap of $443.53 billion, a P/E ratio of 70.92, a P/E/G ratio of 1.13 and a beta of 0.29. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm has a 50-day simple moving average of $254.66 and a two-hundred day simple moving average of $230.55.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm earned $2.97 earnings per share. The firm's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts predict that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie's payout ratio is currently 195.48%.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ABBV has been the topic of several recent research reports. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 5th. JPMorgan Chase & Co. raised their price objective on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Wells Fargo & Company boosted their target price on shares of AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a report on Monday, August 17th. Citigroup upped their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 15th. Finally, Erste Group Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $275.95.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.